3 Undervalued Advanced Medical Equipment & Technology Stocks for Friday, September 20
Discover the top 3 undervalued Advanced Medical Equipment & Technology stocks for Friday, September 20 based on AAII’s Stock Grades.Omar Beirat
Stock Evaluator: HeartSciences Inc. (HSCS)
HeartSciences Inc. HSCS
$3.39
-0.12
-3.42%
September 11, 2026 4:00:00 PM
EST
Volume: 100,657
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Commentary & Analysis
Is Heart Test Laboratories Inc (HSCS) Stock a Good Investment?
Learn more about Heart Test Laboratories Inc's (HSCS) stock grades for Growth and Estimate Revisions and determine whether this Advanced Medical Equipment & Technology stock meets your investment needs.Cynthia McLaughlin
Financial Summary
| Share Statistics | HSCS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13.4 | $385.8 | 7% |
|
| Shares Out (Mil) | 3.1 | 40.8 | 11% |
|
| Institutional Ownership | 16.7% | 83.6% | 8% |
|
| Float (Mil) | 2.7 | 34.7 | 7% |
|
| Beta | 1.79 | 0.88 | 89% |
|
| Avg Daily Volume (000s) | 130 | 291 | 40% |
|
| Price Change (52-week) |
3.6% | 61.6% | 52% |
|
| Growth | HSCS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (29.5%) | (5.8%) | 14% |
|
| EPS (5yr) | 45.7% | 10.4% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (50.2%) | (15.5%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.720) | ($2.620) | ($1.860) | |
| Month Ago EPS | ($0.720) | ($2.620) | ($1.860) | |
| # Rev Up | 2 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.715) | ($2.825) | ($1.930) | |
| Year/Year Chg | (17.8%) | (24.8%) | na | |
| Financials | HSCS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $119 | na |
|
| Net Income (TTM) (Mil) | ($9) | ($9) | 30% |
|
| EPS (TTM) | ($3.482) | ($0.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($3) | 22% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $23 | 12% |
|
| Enterprise Value (Q1) (Mil) | $12 | $371 | 8% |
|
| Valuation | HSCS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 49.00 | 2.74 | 98% |
|
| P/E | na | 25.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | HSCS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.1% | 58.3% | 72% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (192.8%) | (12.7%) | 2% |
|
| ROE | na | (12.3%) | na |
|
| Liabilities to Assets | 95.7% | 46.0% | 93% |
|
| F-Score | 1 | 4 | 1% |
|
HeartSciences Inc. did not pass any screens on 9/11/2026.
